KLK3 and prostate carcinoma: Although a significant decline in prostate cancer-related mortality was observed between 1993 and 2015 (approximately 52%), which has been attributed to earlier detection through prostate-specific antigen (PSA) testing and advances in treatment paradigms, prostate cancer-related mortality appears to have plateaued among men younger than age 70 in recent years [1].